Long intergenic non-protein coding RNA 1629 (LINC01629)

Long intergenic non-protein coding RNA 1629 (LINC01629) is a human long non-coding RNA (lncRNA) encoded on chromosome 14 and classified as an intergenic non-protein coding transcript[5][7][8]. It does not encode a protein, but is instead believed to play a regulatory role at the RNA level[5][8]. LINC01629 is closely linked to the tumor immune microenvironment—particularly in endometrial cancer, where its expression is associated with poor prognosis and altered immune cell infiltration, including decreased macrophage and increased neutrophil presence[1][4]. It is also correlated with the expression of key immune checkpoint molecules such as PD-L1, IDO1, and IDO2, suggesting involvement in immune modulation and potential cancer immune evasion[1][4]. LINC01629 has been identified as a part of multi-lncRNA prediction models for cancer prognosis and the immune landscape, supporting its utility as a prognostic biomarker, though there are no known drugs directly targeting it and it is not considered a canonical therapeutic target[1][3][5][7][8].

Other names

linc-KIAA1737-2LINC01629ENSG00000258602RP11-7F17.7lnc-C14orf166B-3:1NR_133913OTTHUMG00000171577.1NONHSAT037937ENST00000553613